Facebook
Twitter
LinkedIn
ForwardTimely Diagnosis of Alzheimer Disease
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
Category
- Alzheimer Disease
- Dementia
- Neuroimaging
- Primary Care
Format
- Video
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Facilitating Treatment Initiation in Early-Stage Alzheimer Disease
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Category
- Alzheimer Disease
- Dementia
- Integrated Care
- Neuroimaging
- Patient/Physician Communication
- Primary Care
Format
- Video
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Translating Clinical Trial Data into Real-World Practice: Examining CKD Screening and Three Patient Case Profiles
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.
Category
- Renal Disease
- Adherence
- Cardiology
- Comorbidity
- Diagnostic Tools
- Education
- Medical Conditions
- Primary Care
- Side Effects
- Weight
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Part 1: A Review of Schizophrenia
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Part 2: Chasing Cognitive and Negative Symptoms: Unmet Treatment Needs of Patients with Schizophrenia
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Part 3: Impact of Side Effects on Adherence to Schizophrenia Treatment
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Part 4: Balancing Safety and Efficacy with Novel Schizophrenia Treatments
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
An Individualized Approach to PAH Therapy Based on Clinical Data, Goal-Directed Therapy, and Risk Stratification
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
Category
- Cardiology
- Comorbidity
- Education
- Integrated Care
- Medical Conditions
- Pulmonary Disease
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Improving Clinician Awareness of Rett Syndrome and Optimizing Management of Care Across the Patient Lifespan
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies.
Category
- Rett Syndrome
- Child and Adolescent Psychiatry
- Movement Disorders
- Neurology
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Episode 1: Why the Duration Until Onset of Antidepressant Matters
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
Category
- Depression
- Major Depressive Disorder
- Women’s Mental Health
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation